Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price traded up 5.6% during trading on Friday . The company traded as high as C$1.14 and last traded at C$1.13. 28,295 shares changed hands during trading, a decline of 47% from the average session volume of 53,271 shares. The stock had previously closed at C$1.07.
Medicenna Therapeutics Price Performance
The company has a fifty day simple moving average of C$1.02 and a two-hundred day simple moving average of C$1.36. The stock has a market capitalization of C$84.54 million, a price-to-earnings ratio of -3.11 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Savvy Investors Are Raising a Glass for Heineken Stock
- What is a buyback in stocks? A comprehensive guide for investors
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
